The PSA test, the most commonly used biomarker in prostate cancer surveillance, was introduced in Australia in the late-1980s and the rise in its uptake corresponded with a rapid increase in PC incidence [22]. The gene discussed is KLK3; the disease is pachyonychia congenita.